...
首页> 外文期刊>Diagnostic pathology >Variable copy number of mitochondrial DNA (mtDNA) predicts worse prognosis in advanced gastric cancer patients
【24h】

Variable copy number of mitochondrial DNA (mtDNA) predicts worse prognosis in advanced gastric cancer patients

机译:线粒体DNA(mtDNA)的可变拷贝数预测晚期胃癌患者的预后较差

获取原文

摘要

Background Change of mitochondrial DNA (mtDNA) copy number is widely reported in various human cancers, including gastric cancer, and is considered to be an important hallmark of cancers. However, there is remarkably little consensus on the value of variable mtDNA content in the prognostic evaluation of this cancer. Methods Using real-time quantitative PCR approach, we examined mtDNA copy number in a cohort of gastric cancers and normal gastric tissues, and explored the association of variable mtDNA content with clinical outcomes of gastric cancer patients. Results Our data showed that the majority of gastric cancer patients had low mtDNA content as compared to control subjects although the relative mean mtDNA content was higher in the former than the latter. Moreover, we found that variable mtDNA content was strongly associated with lymph node metastasis and cancer-related death of the patients with late-stage tumors. Notably, variable mtDNA content did not affect overall survival of gastric cancer patients, however, we found that increased mtDNA content was associated with poor survival in the patients with late-stage tumors. Conclusion In this study, we demonstrated that variable mtDNA content markedly increased the risk of lymph node metastasis and high mortality of the patients with late-stage tumors. Additionally, we found a strong link between increased mtDNA content and worse survival of the patients with late-stage tumors. Taken together, variable mtDNA content may be a valuable poor prognostic factor for advanced gastric cancer patients. Virtual slides The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/1344721463103353 webcite.
机译:背景技术线粒体DNA(mtDNA)拷贝数的变化在包括胃癌在内的各种人类癌症中得到了广泛报道,并且被认为是癌症的重要标志。然而,关于可变mtDNA含量在该癌症的预后评估中的价值,几乎没有共识。方法采用实时定量PCR方法,检测了一组胃癌和正常胃组织中的mtDNA拷贝数,并探讨了可变mtDNA含量与胃癌患者临床预后的关系。结果我们的数据显示,与对照组相比,大多数胃癌患者的mtDNA含量低,尽管前者的相对平均mtDNA含量高于后者。此外,我们发现晚期肿瘤患者的可变mtDNA含量与淋巴结转移和癌症相关的死亡密切相关。值得注意的是,可变的mtDNA含量不会影响胃癌患者的总体存活率,但是,我们发现,增加的mtDNA含量与晚期肿瘤患者的不良存活率相关。结论在这项研究中,我们证明了可变的mtDNA含量显着增加了晚期肿瘤患者淋巴结转移的风险和高死亡率。此外,我们发现增加的mtDNA含量与晚期肿瘤患者的不良生存之间存在密切的联系。综上所述,对于晚期胃癌患者,可变的mtDNA含量可能是有价值的不良预后因素。虚拟幻灯片可以在此处找到本文的虚拟幻灯片:http://www.diagnosticpathology.diagnomx.eu/vs/1344721463103353网站。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号